LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, June 14, 2019 /PRNewswire/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a
biopharmaceutical company focused on developing novel therapeutics
to treat unmet needs in patients with liver, respiratory and kidney
disease, today announced that four abstracts highlighting
Prometic's progress in developing PBI-4050 as a potential treatment
for both acute kidney injury (AKI) and chronic kidney disease (CKD)
will be presented at the 56th Congress of the European
Renal Association - European Dialysis and Transplant Association
(ERA-EDTA). The Congress will take place on June 13 - 16, 2019 in Budapest, Hungary.
"These pre-clinical results provide additional evidence
demonstrating the anti-fibrotic activity of PBI-4050 and therefore
its potential as a novel therapy for the treatment of AKI and CKD,"
stated Kenneth Galbraith, Chief
Executive Officer of Prometic. "We are encouraged by these results,
which provide additional support for our decision to expand our
development plans for PBI-4050 in fibrosis-related renal
indications in 2020."
An oral presentation will discuss the mechanism of action of
PBI-4050 onto GPR40 and GPR84, two promising biological targets in
the treatment of kidney fibrosis. Results from cellular and animal
models of acute and chronic kidney injuries, including data
demonstrating that PBI-4050 reduced biomarkers associated with
kidney injury from a previously-completed Phase 2 clinical study in
patients with Type 2 diabetes and metabolic syndrome, will be
presented by Dr. Lyne Gagnon, Prometic's Vice-President R&D,
Preclinical, on June 14, 2019 at
8:00 a.m. CEST.
Three poster presentations will highlight the role of the two G
protein-coupled receptors, GPR40 and GPR84, in various models of
kidney injury and associated complications. The following posters
will be presented:
- PBI-4050 Reduces Systemic Inflammation, Electrolyte
Disturbances and Renal Injury in Mice with Sepsis-induced Acute
Kidney Injury; Role of GPR84 (#FP266, June
14, 2019, 9:30 to 10:45 and 16:30 to 17:00).
- Activation of the Free-fatty Acid Receptor GPR40 Improves
Anemia in Mouse Models of Kidney Disease Via a Novel
EPO-Independent Mechanism of Action (#SP345, June 15, 2019, 9:30 to 10:45 and 16:30 to
17:00).
- PBI-4050 Improves Metabolic Regulation and Diabetic
Nephropathy through Reduction of ER Stress,
Pro-Inflammatory/Fibrotic Markers, Galectin-3 Expression and
Inflammatory Cell Infiltration in ob/ob Mouse Model (#SP436,
June 15, 2019, 9:30 to 10:45 and
16:30 to 17:00).
More About PBI-4050
PBI-4050 is an orally active lead drug candidate with excellent
safety and efficacy profiles confirmed in several in vivo
experiments targeting fibrosis. Fibrosis is a very complex process
by which continuing inflammation causes vital organs to lose their
function as normal tissue is replaced by fibrotic scar tissue. The
proof of concept data generated to date confirms our lead drug
candidates' anti-fibrotic activity in several key organs including
the kidneys, lungs, liver and the heart.
About Prometic Life Sciences
Prometic (www.prometic.com) is an innovative biopharmaceutical
corporation with a broad pipeline of small molecule therapeutics
under development to treat unmet needs in patients with liver,
respiratory and kidney disease, including rare diseases. Prometic's
differentiated research involves the study of a new antifibrotic
pathway involving two G-protein-coupled-receptors, GPR40 and GPR84.
These drug candidates have a dual mode-of-action as agonists
("stimulators") of GPR40 and antagonists ("inhibitors") of GPR84.
Our lead drug candidate, PBI-4050, is expected to enter Phase 3
clinical studies for the treatment of Alström Syndrome in 2019. A
second drug candidate, PBI-4547, is expected to enter Phase 1
clinical studies in 2019. Prometic also has leveraged its
experience in bioseparation technologies to isolate and purify
biopharmaceuticals from human plasma. The lead plasma-derived
therapeutic product is Ryplazim™ (plasminogen) for which the
Company expects to file a BLA with the US FDA in 2019 seeking
approval to treat patients with congenital plasminogen deficiency.
The Corporation also operates a contract development and
manufacturing operation in the United
Kingdom, deriving revenue through sales of affinity
chromatography media. Prometic has active business operations in
Canada, the United States, the Isle of Man and the United Kingdom. For more information, please
visit www.prometic.com.
Forward Looking Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2018, under the heading "Risk and
Uncertainties related to Prometic's business". As a result, we
cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations.
View original
content:http://www.prnewswire.com/news-releases/prometic-presents-new-data-on-pbi-4050-and-its-mechanism-of-action-on-kidney-fibrosis-at-the-56th-eraedta-congress-300867663.html
SOURCE ProMetic Life Sciences Inc.